Norris Financial Group’s CRISPR Therapeutics CRSP Stock Holding History

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$345K	Sell	7,257 -585	-7%	-$30.9K	0.11%	70
2025 Q4	$411K	Sell	7,842 -112	-1%	-$6.71K	0.14%	70
2025 Q3	$515K	Sell	7,954 -1,771	-18%	-$102K	0.19%	62
2025 Q2	$473K	Buy	9,725 +48	+0.5%	+$1.86K	0.19%	61
2025 Q1	$329K	Buy	9,677 +3,113	+47%	+$132K	0.15%	67
2024 Q4	$258K	Sell	6,564 -3,790	-37%	-$179K	0.12%	74
2024 Q3	$486K	Buy	10,354 +240	+2%	+$12.2K	0.24%	52
2024 Q2	$546K	Sell	10,114 -2,445	-19%	-$141K	0.28%	51
2024 Q1	$856K	Sell	12,559 -2,308	-16%	-$165K	0.47%	45
2023 Q4	$931K	Buy	14,867 +417	+3%	+$23.1K	0.57%	38
2023 Q3	$656K	Buy	14,450 +2,356	+19%	+$122K	0.45%	44
2023 Q2	$679K	Buy	+12,094	New	+$686K	0.47%	44
2022 Q2	–	Sell	-3,502	Closed	-$220K	–	70
2022 Q1	$220K	Buy	+3,502	New	+$220K	0.13%	74